Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2
Tocilizumab is an IL‐6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We evaluated patients treated with tocilizumab for a SARS‐CoV‐2 infection who were admitted between March...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-11-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.12894 |
| _version_ | 1819097542496878592 |
|---|---|
| author | Russell M. Petrak Nathan C. Skorodin Nicholas W. Van Hise Robert M. Fliegelman Jonathan Pinsky Vishal Didwania Michael Anderson Melina Diaz Kairav Shah Vishnu V. Chundi David W. Hines Brian P. Harting Kamo Sidwha Brian Yu Paul Brune Anjum Owaisi David Beezhold Joseph Kent Dana Vais Alice Han Neethi Gowda Nishi Sahgal Jan Silverman Jonathan Stake Jenie Nepomuceno Renuka Heddurshetti |
| author_facet | Russell M. Petrak Nathan C. Skorodin Nicholas W. Van Hise Robert M. Fliegelman Jonathan Pinsky Vishal Didwania Michael Anderson Melina Diaz Kairav Shah Vishnu V. Chundi David W. Hines Brian P. Harting Kamo Sidwha Brian Yu Paul Brune Anjum Owaisi David Beezhold Joseph Kent Dana Vais Alice Han Neethi Gowda Nishi Sahgal Jan Silverman Jonathan Stake Jenie Nepomuceno Renuka Heddurshetti |
| author_sort | Russell M. Petrak |
| collection | DOAJ |
| description | Tocilizumab is an IL‐6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We evaluated patients treated with tocilizumab for a SARS‐CoV‐2 infection who were admitted between March 13, 2020, and April 16, 2020. This was a multicenter study with data collected by chart review both retrospectively and concurrently. Parameters evaluated included age, sex, race, use of mechanical ventilation (MV), usage of steroids and vasopressors, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within 1 day of intubation. Late dosing was defined as a dose administered > 1 day after intubation. In the absence of MV, the timing of the dose was related to the patient’s date of admission only. We evaluated 145 patients. The average age was 58.1 years, 64% were men, 68.3% had comorbidities, and 60% received steroid therapy. Disposition of patients was 48.3% discharged and 29.3% died, of which 43.9% were African American. MV was required in 55.9%, of which 34.5% died. Avoidance of MV (P = 0.002) and increased survival (P < 0.001) was statistically associated with early dosing. Tocilizumab therapy was effective at decreasing mortality and should be instituted early in the management of critically ill patients with coronavirus disease 2019) COVID‐19). |
| first_indexed | 2024-12-22T00:16:45Z |
| format | Article |
| id | doaj.art-8f2e979c953546579043c6871302879b |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-12-22T00:16:45Z |
| publishDate | 2021-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-8f2e979c953546579043c6871302879b2022-12-21T18:45:16ZengWileyClinical and Translational Science1752-80541752-80622021-11-011462146215110.1111/cts.12894Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2Russell M. Petrak0Nathan C. Skorodin1Nicholas W. Van Hise2Robert M. Fliegelman3Jonathan Pinsky4Vishal Didwania5Michael Anderson6Melina Diaz7Kairav Shah8Vishnu V. Chundi9David W. Hines10Brian P. Harting11Kamo Sidwha12Brian Yu13Paul Brune14Anjum Owaisi15David Beezhold16Joseph Kent17Dana Vais18Alice Han19Neethi Gowda20Nishi Sahgal21Jan Silverman22Jonathan Stake23Jenie Nepomuceno24Renuka Heddurshetti25Metro Infectious Disease Consultants Burr Ridge Illinois USAMetro Infectious Disease Consultants Burr Ridge Illinois USAMetro Infectious Disease Consultants Burr Ridge Illinois USAMetro Infectious Disease Consultants Burr Ridge Illinois USAMetro Infectious Disease Consultants Naperville Illinois USAMetro Infectious Disease Consultants Elmhurst Illinois USAMetro Infectious Disease Consultants Kankakee Illinois USAMetro Infectious Disease Consultants Atlanta Georgia USAMetro Infectious Disease Consultants Atlanta Georgia USAMetro Infectious Disease Consultants Chicago Illinois USAMetro Infectious Disease Consultants Chicago Illinois USAMetro Infectious Disease Consultants Downers Grove Illinois USAMetro Infectious Disease Consultants Chicago Illinois USAMetro Infectious Disease Consultants Chicago Illinois USAMetro Infectious Disease Consultants Kansas City Missouri USAMetro Infectious Disease Consultants Bolingbrook Illinois USAMetro Infectious Disease Consultants Elmhurst Illinois USAMetro Infectious Disease Consultants Oak Lawn Illinois USAMetro Infectious Disease Consultants Chicago Illinois USAMetro Infectious Disease Consultants Chicago Illinois USAMetro Infectious Disease Consultants Troy Michigan USAMetro Infectious Disease Consultants Hinsdale Illinois USAMetro Infectious Disease Consultants, Royal Oak Michigan USAMetro Infectious Disease Consultants Waukegan Illinois USAMetro Infectious Disease Consultants McHenry Illinois USAMetro Infectious Disease Consultants Detroit Michigan USATocilizumab is an IL‐6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We evaluated patients treated with tocilizumab for a SARS‐CoV‐2 infection who were admitted between March 13, 2020, and April 16, 2020. This was a multicenter study with data collected by chart review both retrospectively and concurrently. Parameters evaluated included age, sex, race, use of mechanical ventilation (MV), usage of steroids and vasopressors, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within 1 day of intubation. Late dosing was defined as a dose administered > 1 day after intubation. In the absence of MV, the timing of the dose was related to the patient’s date of admission only. We evaluated 145 patients. The average age was 58.1 years, 64% were men, 68.3% had comorbidities, and 60% received steroid therapy. Disposition of patients was 48.3% discharged and 29.3% died, of which 43.9% were African American. MV was required in 55.9%, of which 34.5% died. Avoidance of MV (P = 0.002) and increased survival (P < 0.001) was statistically associated with early dosing. Tocilizumab therapy was effective at decreasing mortality and should be instituted early in the management of critically ill patients with coronavirus disease 2019) COVID‐19).https://doi.org/10.1111/cts.12894 |
| spellingShingle | Russell M. Petrak Nathan C. Skorodin Nicholas W. Van Hise Robert M. Fliegelman Jonathan Pinsky Vishal Didwania Michael Anderson Melina Diaz Kairav Shah Vishnu V. Chundi David W. Hines Brian P. Harting Kamo Sidwha Brian Yu Paul Brune Anjum Owaisi David Beezhold Joseph Kent Dana Vais Alice Han Neethi Gowda Nishi Sahgal Jan Silverman Jonathan Stake Jenie Nepomuceno Renuka Heddurshetti Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2 Clinical and Translational Science |
| title | Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2 |
| title_full | Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2 |
| title_fullStr | Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2 |
| title_full_unstemmed | Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2 |
| title_short | Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2 |
| title_sort | tocilizumab as a therapeutic agent for critically ill patients infected with sars cov 2 |
| url | https://doi.org/10.1111/cts.12894 |
| work_keys_str_mv | AT russellmpetrak tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT nathancskorodin tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT nicholaswvanhise tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT robertmfliegelman tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT jonathanpinsky tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT vishaldidwania tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT michaelanderson tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT melinadiaz tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT kairavshah tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT vishnuvchundi tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT davidwhines tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT brianpharting tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT kamosidwha tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT brianyu tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT paulbrune tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT anjumowaisi tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT davidbeezhold tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT josephkent tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT danavais tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT alicehan tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT neethigowda tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT nishisahgal tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT jansilverman tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT jonathanstake tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT jenienepomuceno tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 AT renukaheddurshetti tocilizumabasatherapeuticagentforcriticallyillpatientsinfectedwithsarscov2 |